{"id":7110,"date":"2026-03-26T13:11:09","date_gmt":"2026-03-26T10:11:09","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=7110"},"modified":"2026-03-29T14:35:32","modified_gmt":"2026-03-29T11:35:32","slug":"dmd-donations-how-associations-use-donations","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/dmd-donations-how-associations-use-donations\/","title":{"rendered":"Duchenne Kas Distrofisi (DMD) Derneklerinde Hesap Verebilirlik Krizi: Ba\u011f\u0131\u015flar Neden \u00d6l\u00e7\u00fclebilir Sonu\u00e7lara Yol A\u00e7mal\u0131d\u0131r?"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>DMD dernekleri ald\u0131klar\u0131 ba\u011f\u0131\u015flar\u0131 nereye harc\u0131yor ve bu ba\u011f\u0131\u015flar\u0131n ne kadar\u0131 ger\u00e7ekten bilimsel ara\u015ft\u0131rmalar\u0131 ve klinik denemeleri destekliyor?<\/strong> Ba\u011f\u0131\u015flar, hayatlar\u0131 de\u011fi\u015ftirebilecek terapilere mi y\u00f6nlendiriliyor yoksa idari masraflar, konferanslar ve seyahatler gibi giderlere mi da\u011f\u0131l\u0131yor? Ayr\u0131nt\u0131l\u0131 mali d\u00f6k\u00fcmler neden genellikle belirsiz veya eri\u015filmesi zor? Ba\u011f\u0131\u015f\u00e7\u0131lar ve aileler, katk\u0131da bulunduklar\u0131 paran\u0131n \u00f6l\u00e7\u00fclebilir sonu\u00e7lar\u0131n\u0131 g\u00f6rebiliyorlar m\u0131?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu makale, DMD dernekleri i\u00e7indeki ba\u011f\u0131\u015flar\u0131n da\u011f\u0131t\u0131m\u0131n\u0131 ele\u015ftirel bir \u015fekilde de\u011ferlendiriyor, yap\u0131sal verimsizlikleri vurguluyor ve \u015feffafl\u0131k, hesap verebilirlik ve \u00f6l\u00e7\u00fclebilir etki metriklerine do\u011fru bir paradigma de\u011fi\u015fimini savunuyor.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#the-role-of-dmd-associations-in-the-therapeutic-ecosystem\">DMD Derneklerinin Tedavi Ekosistemindeki Rol\u00fc<\/a><ul><li><a href=\"#historical-contributions-of-patient-advocacy-organizations\">Hasta Haklar\u0131 Savunuculu\u011fu \u00d6rg\u00fctlerinin Tarihsel Katk\u0131lar\u0131<\/a><\/li><li><a href=\"#the-shift-toward-large-scale-fundraising\">B\u00fcy\u00fck \u00d6l\u00e7ekli Ba\u011f\u0131\u015f Toplama Y\u00f6ntemlerine Do\u011fru Ge\u00e7i\u015f<\/a><\/li><\/ul><\/li><li><a href=\"#where-do-the-donations-actually-go\">Ba\u011f\u0131\u015flar Ger\u00e7ekte Nereye Gidiyor?<\/a><ul><li><a href=\"#general-allocation-patterns\">Genel Tahsis Kal\u0131plar\u0131<\/a><\/li><li><a href=\"#research-vs-non-research-spending\">Ara\u015ft\u0131rma Harcamalar\u0131 ve Ara\u015ft\u0131rma D\u0131\u015f\u0131 Harcamalar<\/a><\/li><\/ul><\/li><li><a href=\"#the-problem-with-conferences-and-travel-expenditures\">Konferanslar ve Seyahat Giderleriyle \u0130lgili Sorunlar<\/a><ul><li><a href=\"#scientific-conferences-value-vs-reality\">Bilimsel Konferanslar: De\u011fer ve Ger\u00e7eklik Aras\u0131ndaki Fark<\/a><\/li><li><a href=\"#the-dmd-specific-concern\">DMD&#039;ye \u00d6zg\u00fc Endi\u015fe<\/a><\/li><\/ul><\/li><li><a href=\"#the-transparency-deficit\">\u015eeffafl\u0131k A\u00e7\u0131\u011f\u0131<\/a><ul><li><a href=\"#lack-of-detailed-public-reporting\">Ayr\u0131nt\u0131l\u0131 Kamuoyu Bilgilendirmesinin Eksikli\u011fi<\/a><\/li><li><a href=\"#absence-of-measurable-kp-is\">\u00d6l\u00e7\u00fclebilir Performans G\u00f6stergelerinin Yoklu\u011fu<\/a><\/li><\/ul><\/li><li><a href=\"#ethical-implications-of-inefficient-fund-allocation\">Ba\u011f\u0131\u015flar\u0131n Etkisiz \u0130\u015flerde Harcanmas\u0131n\u0131n Sonu\u00e7lar\u0131<\/a><ul><li><a href=\"#opportunity-cost-in-a-fatal-disease\">\u00d6l\u00fcmc\u00fcl Bir Hastal\u0131kta F\u0131rsat Maliyeti<\/a><\/li><li><a href=\"#donor-trust-and-moral-responsibility\">Ba\u011f\u0131\u015f\u00e7\u0131 G\u00fcveni ve Ahlaki Sorumluluk<\/a><\/li><\/ul><\/li><li><a href=\"#case-for-measurable-impact-frameworks\">\u00d6l\u00e7\u00fclebilir Etki \u00c7er\u00e7eveleri \u0130\u00e7in Gerek\u00e7eler<\/a><ul><li><a href=\"#outcome-based-funding-models\">Sonu\u00e7 Odakl\u0131 Finansman Modelleri<\/a><\/li><li><a href=\"#suggested-metrics\">\u00d6nerilen \u00d6l\u00e7\u00fctler<\/a><ul><li><a href=\"#research-impact-metrics\">Ara\u015ft\u0131rma Etki \u00d6l\u00e7\u00fctleri<\/a><\/li><li><a href=\"#clinical-impact-metrics\">Klinik Etki \u00d6l\u00e7\u00fctleri<\/a><\/li><li><a href=\"#financial-efficiency-metrics\">Finansal Verimlilik \u00d6l\u00e7\u00fctleri<\/a><\/li><\/ul><\/li><\/ul><\/li><li><a href=\"#the-need-for-radical-transparency\">Radikal \u015eeffafl\u0131\u011fa Duyulan \u0130htiya\u00e7<\/a><ul><li><a href=\"#open-financial-reporting\">A\u00e7\u0131k Finansal Raporlama<\/a><\/li><li><a href=\"#public-dashboards\">Herkese A\u00e7\u0131k Kontrol Panelleri<\/a><\/li><\/ul><\/li><li><a href=\"#recommendations-for-reform\">Reform \u00d6nerileri<\/a><ul><li><a href=\"#structural-reforms\">Yap\u0131sal Reformlar<\/a><\/li><li><a href=\"#policy-recommendations\">Politika \u00d6nerileri<\/a><\/li><li><a href=\"#cultural-shift\">K\u00fclt\u00fcrel De\u011fi\u015fim<\/a><\/li><\/ul><\/li><li><a href=\"#beyond-assistance-the-true-mission-of-dmd-associations\">Yard\u0131m\u0131n \u00d6tesinde: DMD Derneklerinin Ger\u00e7ek Misyonu<\/a><\/li><li><a href=\"#if-no-research-and-no-clinical-trial-rethink-about-making-donation\">E\u011fer ara\u015ft\u0131rma ve klinik deneme yoksa: Ba\u011f\u0131\u015f yapmay\u0131 yeniden d\u00fc\u015f\u00fcn\u00fcn.<\/a><\/li><li><a href=\"#critical-fa-qs-from-dmd-families-demanding-transparency-and-real-impact\">DMD Hastal\u0131\u011f\u0131 Olan Ailelerden Kritik S\u0131k\u00e7a Sorulan Sorular: \u015eeffafl\u0131k ve Ger\u00e7ek Etki Talebi<\/a><ul><li><a href=\"#faq-question-1774515397458\">Toplad\u0131\u011f\u0131n\u0131z ba\u011f\u0131\u015flar\u0131n ne kadar\u0131 do\u011frudan bilimsel ara\u015ft\u0131rmalara ve klinik denemelere gidiyor?<\/a><\/li><li><a href=\"#faq-question-1774515805118\">Finanse etti\u011finiz ara\u015ft\u0131rmadan elde etti\u011finiz \u00f6l\u00e7\u00fclebilir sonu\u00e7lar\u0131 g\u00f6sterebilir misiniz?<\/a><\/li><li><a href=\"#faq-question-1774515816908\">Ba\u011f\u0131\u015flar\u0131m\u0131z\u0131n ne kadar\u0131 seyahat, konferans ve toplant\u0131lara harcan\u0131yor?<\/a><\/li><li><a href=\"#faq-question-1774515823379\">Ayr\u0131nt\u0131l\u0131 finansal raporlar neden tam olarak \u015feffaf ve anla\u015f\u0131lmas\u0131 kolay de\u011fil?<\/a><\/li><li><a href=\"#faq-question-1774515836543\">Finanse etti\u011finiz projelerin ba\u015far\u0131 oran\u0131n\u0131 takip ediyor musunuz?<\/a><\/li><li><a href=\"#faq-question-1774515871509\">Ara\u015ft\u0131rma projelerine fon sa\u011flan\u0131p sa\u011flanmayaca\u011f\u0131na karar verirken hangi kriterleri kullan\u0131yorsunuz?<\/a><\/li><li><a href=\"#faq-question-1774515921814\">Ba\u011f\u0131\u015flanan fonlar\u0131n d\u00fc\u015f\u00fck etkili veya tekrarlayan faaliyetlere harcanmamas\u0131n\u0131 nas\u0131l sa\u011fl\u0131yorsunuz?<\/a><\/li><li><a href=\"#faq-question-1774515949457\">Ba\u011f\u0131\u015f\u00e7\u0131lara neden ilerleme durumu panolar\u0131 veya ger\u00e7ek zamanl\u0131 g\u00fcncellemeler sunulmuyor?<\/a><\/li><li><a href=\"#faq-question-1774515973917\">B\u00fct\u00e7enizin y\u00fczde ka\u00e7\u0131 y\u00f6netim giderlerine ve maa\u015flara harcan\u0131yor?<\/a><\/li><li><a href=\"#faq-question-1774515992914\">E\u011fer ba\u011f\u0131\u015flar \u00f6l\u00e7\u00fclebilir bir ilerleme sa\u011flam\u0131yorsa, hangi hesap verebilirlik mekanizmalar\u0131 mevcuttur?<\/a><\/li><\/ul><\/li><li><a href=\"#closing-perspective\">Kapan\u0131\u015f Bak\u0131\u015f A\u00e7\u0131s\u0131<\/a><\/li><li><a href=\"#final-thoughts\">Son D\u00fc\u015f\u00fcnceler<\/a><\/li><li><a href=\"#sources-and-academic-references\">Kaynaklar ve Akademik Referanslar<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-role-of-dmd-associations-in-the-therapeutic-ecosystem\"><strong>DMD Derneklerinin Tedavi Ekosistemindeki Rol\u00fc<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"historical-contributions-of-patient-advocacy-organizations\"><strong>Hasta Haklar\u0131 Savunuculu\u011fu \u00d6rg\u00fctlerinin Tarihsel Katk\u0131lar\u0131<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Hasta haklar\u0131 savunucusu \u00f6rg\u00fctler, nadir hastal\u0131k ara\u015ft\u0131rmalar\u0131nda \u00e7ok \u00f6nemli bir rol oynam\u0131\u015ft\u0131r. Parent Project Muscular Dystrophy (PPMD), Muscular Dystrophy Association (MDA) ve di\u011ferleri gibi gruplar \u015funlar\u0131 yapm\u0131\u015ft\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Finanse edilen erken a\u015fama ara\u015ft\u0131rma<\/li>\n\n\n\n<li>Hasta kay\u0131tlar\u0131n\u0131n kolayla\u015ft\u0131r\u0131lmas\u0131<\/li>\n\n\n\n<li>H\u0131zland\u0131r\u0131lm\u0131\u015f d\u00fczenleyici yollar<\/li>\n\n\n\n<li>Klinik deneme kat\u0131l\u0131mc\u0131 al\u0131m\u0131na destek sa\u011flanmak<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6rne\u011fin:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Bushby, savunuculuk gruplar\u0131 taraf\u0131ndan desteklenen koordineli bak\u0131m a\u011flar\u0131n\u0131n \u00f6nemini vurgulam\u0131\u015ft\u0131r.<\/li>\n\n\n\n<li>NIH, hasta \u00f6rg\u00fctlerinin nadir hastal\u0131klar alan\u0131ndaki translasyonel ara\u015ft\u0131rmalar\u0131n finansman\u0131na \u00f6nemli \u00f6l\u00e7\u00fcde katk\u0131da bulundu\u011funu kabul etmi\u015ftir.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"the-shift-toward-large-scale-fundraising\"><strong>B\u00fcy\u00fck \u00d6l\u00e7ekli Ba\u011f\u0131\u015f Toplama Y\u00f6ntemlerine Do\u011fru Ge\u00e7i\u015f<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Zamanla, bir\u00e7ok DMD derne\u011fi k\u00fc\u00e7\u00fck, g\u00f6n\u00fcll\u00fcler taraf\u0131ndan y\u00f6netilen kurulu\u015flardan b\u00fcy\u00fck ba\u011f\u0131\u015f toplama kurumlar\u0131na d\u00f6n\u00fc\u015ft\u00fc. Bu d\u00f6n\u00fc\u015f\u00fcm \u015funlar\u0131 beraberinde getirdi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Profesyonelle\u015ftirilmi\u015f y\u00f6netim yap\u0131lar\u0131<\/li>\n\n\n\n<li>Pazarlama ve ba\u011f\u0131\u015f toplama kampanyalar\u0131<\/li>\n\n\n\n<li>Artan i\u015fletme maliyetleri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu b\u00fcy\u00fcme, ba\u011f\u0131\u015f toplama kapasitesini geni\u015fletirken, ayn\u0131 zamanda idari geni\u015flemenin ara\u015ft\u0131rma fonlama \u00f6ncelikleriyle rekabet etmeye ba\u015flamas\u0131yla ortaya \u00e7\u0131kan misyon sapmas\u0131 riskini de beraberinde getirdi.<\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"where-do-the-donations-actually-go\"><strong>Ba\u011f\u0131\u015flar Ger\u00e7ekte Nereye Gidiyor?<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"general-allocation-patterns\"><strong>Genel Tahsis Kal\u0131plar\u0131<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">B\u00fcy\u00fck kar amac\u0131 g\u00fctmeyen kurulu\u015flar\u0131n kamuya a\u00e7\u0131k mali raporlar\u0131n\u0131n analizi, ortak bir da\u011f\u0131l\u0131m modelini ortaya koymaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Program Hizmetleri (Ara\u015ft\u0131rma + Hasta Deste\u011fi):<\/strong> 50\u201375%<\/li>\n\n\n\n<li><strong>Y\u00f6netim Giderleri:<\/strong> 10\u201325%<\/li>\n\n\n\n<li><strong>Ba\u011f\u0131\u015f Toplama Giderleri:<\/strong> 10\u201325%<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ancak, &quot;program hizmetleri&quot; kategorisi genellikle geni\u015f bir \u015fekilde tan\u0131mlan\u0131r ve \u015funlar\u0131 i\u00e7erir:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Konferanslar<\/li>\n\n\n\n<li>Fark\u0131ndal\u0131k kampanyalar\u0131<\/li>\n\n\n\n<li>E\u011fitim at\u00f6lyeleri<\/li>\n\n\n\n<li>Seyahat masraflar\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu durum kritik bir belirsizlik yarat\u0131yor:<br><strong>&quot;Program harcamalar\u0131n\u0131n&quot; ne kadar\u0131 somut bilimsel ilerlemeyle sonu\u00e7lan\u0131yor?<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"research-vs-non-research-spending\"><strong>Ara\u015ft\u0131rma Harcamalar\u0131 ve Ara\u015ft\u0131rma D\u0131\u015f\u0131 Harcamalar<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Kar amac\u0131 g\u00fctmeyen kurulu\u015flar\u0131n verimlili\u011fini inceleyen \u00e7al\u0131\u015fmalar (\u00f6rne\u011fin, Porter ve Kramer, <em>Harvard \u0130\u015fletme \u0130ncelemesi<\/em>, (1999; 2019&#039;da g\u00fcncellenen \u00e7er\u00e7eveler) \u015funlar\u0131 vurgulamaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bir\u00e7ok kar amac\u0131 g\u00fctmeyen kurulu\u015f, \u00e7e\u015fitli faaliyetleri &quot;program giderleri&quot; ba\u015fl\u0131\u011f\u0131 alt\u0131nda toplayarak etkiyi oldu\u011fundan fazla g\u00f6steriyor.\u201c<\/strong><\/li>\n\n\n\n<li>Bu harcamalar\u0131n yaln\u0131zca bir alt k\u00fcmesi \u00f6l\u00e7\u00fclebilir sonu\u00e7lara yol a\u00e7maktad\u0131r (\u00f6rne\u011fin, yay\u0131nlar, klinik \u00e7al\u0131\u015fmalar, FDA onaylar\u0131).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">DMD ba\u011flam\u0131nda:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Do\u011frudan ara\u015ft\u0131rmalara b\u00fct\u00e7e ay\u0131rma, toplam harcamalar\u0131n yaln\u0131zca k\u00fc\u00e7\u00fck bir b\u00f6l\u00fcm\u00fcn\u00fc temsil ediyor.<\/strong><\/li>\n\n\n\n<li>\u00d6nemli miktardaki ba\u011f\u0131\u015flar \u015fu alanlara tahsis edilebilir:\n<ul class=\"wp-block-list\">\n<li><strong>Eyleme d\u00f6n\u00fc\u015ft\u00fcr\u00fclebilir sonu\u00e7lar\u0131 s\u0131n\u0131rl\u0131 olan konferanslar<\/strong><\/li>\n\n\n\n<li>Dan\u0131\u015fma kurulu seyahatleri<\/li>\n\n\n\n<li><strong>\u00d6l\u00e7\u00fclebilir politika etkisi olmayan savunuculuk eylemleri<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-problem-with-conferences-and-travel-expenditures\"><strong>Konferanslar ve Seyahat Giderleriyle \u0130lgili Sorunlar<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"scientific-conferences-value-vs-reality\"><strong>Bilimsel Konferanslar: De\u011fer ve Ger\u00e7eklik Aras\u0131ndaki Fark<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bilimsel konferanslar genellikle \u015fu gerek\u00e7elerle d\u00fczenlenir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Bilgi payla\u015f\u0131m platformlar\u0131<\/li>\n\n\n\n<li>A\u011f olu\u015fturma f\u0131rsatlar\u0131<\/li>\n\n\n\n<li>\u0130\u015fbirli\u011fi ve ortakl\u0131k kurmak<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ancak ampirik kan\u0131tlar, kar\u0131\u015f\u0131k sonu\u00e7lar g\u00f6stermektedir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ioannidis (2012), bir\u00e7ok biyomedikal konferans\u0131n s\u0131n\u0131rl\u0131 ve tekrarlanabilir etki yaratt\u0131\u011f\u0131n\u0131 savundu.<\/li>\n\n\n\n<li>Research Policy dergisinde 2018 y\u0131l\u0131nda yap\u0131lan bir analiz, konferanslara kat\u0131l\u0131m\u0131n her zaman y\u00fcksek etkili yay\u0131nlara d\u00f6n\u00fc\u015fmedi\u011fini ortaya koydu.<sup data-fn=\"96084803-54f1-4918-9709-737f9813c4a8\" class=\"fn\"><a id=\"96084803-54f1-4918-9709-737f9813c4a8-link\" href=\"#96084803-54f1-4918-9709-737f9813c4a8\">1<\/a><\/sup><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"the-dmd-specific-concern\"><strong>DMD&#039;ye \u00d6zg\u00fc Endi\u015fe<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DMD derneklerinde, konferansla ilgili harcamalar genellikle \u015funlar\u0131 i\u00e7erir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Personel ve y\u00f6netim kurulu \u00fcyeleri i\u00e7in uluslararas\u0131 seyahat<\/li>\n\n\n\n<li>Konaklama ve a\u011f\u0131rlama maliyetleri<\/li>\n\n\n\n<li>B\u00fcy\u00fck \u00f6l\u00e7ekli etkinliklere sponsorluk<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>As\u0131l sorun konferanslar\u0131n varl\u0131\u011f\u0131 de\u011fil, \u00f6l\u00e7\u00fclebilir sonu\u00e7lar\u0131n eksikli\u011fidir; \u00f6rne\u011fin:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Yeni klinik \u00e7al\u0131\u015fma ba\u015flat\u0131lmas\u0131<\/li>\n\n\n\n<li>Ortakla\u015fa yay\u0131nlanan ara\u015ft\u0131rmalar<\/li>\n\n\n\n<li>B\u00fcrokratik i\u015flemlerin h\u0131zlanmas\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bunlar olmadan, bu t\u00fcr harcamalar sonu\u00e7 odakl\u0131 olmaktan ziyade sembolik hale gelme riski ta\u015f\u0131r.<\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-transparency-deficit\"><strong>\u015eeffafl\u0131k A\u00e7\u0131\u011f\u0131<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"lack-of-detailed-public-reporting\"><strong>Ayr\u0131nt\u0131l\u0131 Kamuoyu Bilgilendirmesinin Eksikli\u011fi<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bir\u00e7ok DMD derne\u011fi y\u0131ll\u0131k raporlar yay\u0131nlar, ancak bu raporlarda genellikle \u015fu hususlar eksiktir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ara\u015ft\u0131rma ve ara\u015ft\u0131rma d\u0131\u015f\u0131 harcamalar\u0131n ayr\u0131nt\u0131l\u0131 d\u00f6k\u00fcm\u00fc<\/li>\n\n\n\n<li>Sonu\u00e7 odakl\u0131 raporlama<\/li>\n\n\n\n<li>B\u00fcy\u00fck harcamalar\u0131n maliyet-fayda analizi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bunun yerine, raporlarda s\u0131kl\u0131kla \u015fu hususlar vurgulanmaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Toplanan toplam ba\u011f\u0131\u015f miktar\u0131<\/li>\n\n\n\n<li>D\u00fczenlenen etkinlik say\u0131s\u0131<\/li>\n\n\n\n<li>Genel misyon bildirimleri<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"absence-of-measurable-kp-is\"><strong>\u00d6l\u00e7\u00fclebilir Performans G\u00f6stergelerinin Yoklu\u011fu<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Temel Performans G\u00f6stergeleri (KPI&#039;lar) nadiren bilimsel olarak anlaml\u0131 bir \u015fekilde tan\u0131mlan\u0131r. \u00d6rne\u011fin:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Yayg\u0131n ancak yetersiz performans g\u00f6stergeleri:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Kat\u0131ld\u0131\u011f\u0131 konferans say\u0131s\u0131<\/li>\n\n\n\n<li>Kat\u0131lan hasta say\u0131s\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kritik performans g\u00f6stergeleri eksik:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Hakemli yay\u0131nlarla sonu\u00e7lanan fonlu ara\u015ft\u0131rma say\u0131s\u0131<\/li>\n\n\n\n<li>Ba\u015flat\u0131lan veya tamamlanan klinik ara\u015ft\u0131rma say\u0131s\u0131<\/li>\n\n\n\n<li>D\u00fczenleyici onaylara katk\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu eksiklik, ba\u011f\u0131\u015f\u00e7\u0131lar\u0131n hay\u0131rsever yat\u0131r\u0131m getirisini (ROPI) de\u011ferlendirmelerini engellemektedir.<\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ethical-implications-of-inefficient-fund-allocation\"><strong>Ba\u011f\u0131\u015flar\u0131n Etkisiz \u0130\u015flerde Harcanmas\u0131n\u0131n Sonu\u00e7lar\u0131<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"opportunity-cost-in-a-fatal-disease\"><strong>\u00d6l\u00fcmc\u00fcl Bir Hastal\u0131kta F\u0131rsat Maliyeti<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DMD, h\u0131zla ilerleyen ve \u00f6l\u00fcmc\u00fcl bir hastal\u0131kt\u0131r. Verimsizlik nedeniyle kaybedilen her y\u0131l \u015funlara kar\u015f\u0131l\u0131k gelir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Mevcut hastalar i\u00e7in hayatta kalma oran\u0131nda azalma<\/li>\n\n\n\n<li>Tedavilere eri\u015fimde gecikmeler<\/li>\n\n\n\n<li>Ka\u00e7\u0131r\u0131lan ara\u015ft\u0131rma f\u0131rsatlar\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu ba\u011flamda, ba\u011f\u0131\u015flar\u0131n yanl\u0131\u015f y\u00f6nlendirilmesi sadece verimsiz olmakla kalmaz, ayn\u0131 zamanda etik a\u00e7\u0131dan da \u00f6nemli sonu\u00e7lar do\u011furur.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"donor-trust-and-moral-responsibility\"><strong>Ba\u011f\u0131\u015f\u00e7\u0131 G\u00fcveni ve Ahlaki Sorumluluk<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u011f\u0131\u015f\u00e7\u0131lar, ba\u011f\u0131\u015flar\u0131n\u0131n \u015fu ama\u00e7larla kullan\u0131laca\u011f\u0131 beklentisiyle katk\u0131da bulunurlar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Tedavileri h\u0131zland\u0131rmak<\/li>\n\n\n\n<li>Hastalar\u0131n durumlar\u0131n\u0131 iyile\u015ftirmek<\/li>\n\n\n\n<li>Bilimsel \u00e7al\u0131\u015fmalar\u0131 desteklemek<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u011f\u0131\u015flar\u0131n etkin bir \u015fekilde kullan\u0131lmamas\u0131 \u015fu hususlar\u0131n ihlali anlam\u0131na gelir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Etik sorumluluk<\/li>\n\n\n\n<li>Vekalet g\u00f6revi<\/li>\n\n\n\n<li>Kamu g\u00fcveni<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"case-for-measurable-impact-frameworks\"><strong>\u00d6l\u00e7\u00fclebilir Etki \u00c7er\u00e7eveleri \u0130\u00e7in Gerek\u00e7eler<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"outcome-based-funding-models\"><strong>Sonu\u00e7 Odakl\u0131 Finansman Modelleri<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DMD dernekleri, a\u015fa\u011f\u0131dakiler de dahil olmak \u00fczere, etki odakl\u0131 finansman \u00e7er\u00e7evelerini benimsemelidir:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>D\u00f6n\u00fcm noktas\u0131na dayal\u0131 hibe da\u011f\u0131t\u0131m\u0131<\/li>\n\n\n\n<li>Performansa ba\u011fl\u0131 finansman<\/li>\n\n\n\n<li>Ba\u011f\u0131ms\u0131z bilimsel inceleme panelleri<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"suggested-metrics\"><strong>\u00d6nerilen \u00d6l\u00e7\u00fctler<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Sa\u011flam bir de\u011ferlendirme sistemi \u015funlar\u0131 i\u00e7ermelidir:<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"research-impact-metrics\"><strong>Ara\u015ft\u0131rma Etki \u00d6l\u00e7\u00fctleri<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Hakemli yay\u0131n say\u0131s\u0131<\/li>\n\n\n\n<li>At\u0131f etkisi (h-endeks katk\u0131s\u0131)<\/li>\n\n\n\n<li>Veri payla\u015f\u0131m\u0131 ve tekrarlanabilirlik<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"clinical-impact-metrics\"><strong>Klinik Etki \u00d6l\u00e7\u00fctleri<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ba\u015flat\u0131lan denemeler<\/li>\n\n\n\n<li>Tamamlanan denemeler<\/li>\n\n\n\n<li>Kay\u0131tl\u0131 hastalar<\/li>\n\n\n\n<li>B\u00fcrokrasiden al\u0131nan onaylar<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"financial-efficiency-metrics\"><strong>Finansal Verimlilik \u00d6l\u00e7\u00fctleri<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ba\u011f\u0131\u015flar\u0131n do\u011frudan ara\u015ft\u0131rmaya ayr\u0131lan y\u00fczdesi<\/li>\n\n\n\n<li>Bilimsel \u00e7\u0131kt\u0131 ba\u015f\u0131na maliyet<\/li>\n\n\n\n<li>Y\u00f6netimsel genel gider oran\u0131<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-need-for-radical-transparency\"><strong>Radikal \u015eeffafl\u0131\u011fa Duyulan \u0130htiya\u00e7<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"open-financial-reporting\"><strong>A\u00e7\u0131k Finansal Raporlama<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Dernekler \u015funlar\u0131 yay\u0131nlamal\u0131d\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Kalem kalem b\u00fct\u00e7eler<\/li>\n\n\n\n<li>Hibe tahsis detaylar\u0131<\/li>\n\n\n\n<li>Proje d\u00fczeyindeki sonu\u00e7lar<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"public-dashboards\"><strong>Herkese A\u00e7\u0131k Kontrol Panelleri<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Modern bir yakla\u015f\u0131m \u015funlar\u0131 i\u00e7erecektir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ger\u00e7ek zamanl\u0131 ba\u011f\u0131\u015f sunumu<\/li>\n\n\n\n<li>Ara\u015ft\u0131rma ilerleme g\u00f6sterge panelleri<\/li>\n\n\n\n<li>Finanse edilen \u00e7al\u0131\u015fma sonu\u00e7lar\u0131na kamuoyunun eri\u015fimi<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"recommendations-for-reform\"><strong>Reform \u00d6nerileri<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"structural-reforms\"><strong>Yap\u0131sal Reformlar<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Y\u00f6netimsel y\u00fck\u00fc \u00f6nceden belirlenmi\u015f kademelerle s\u0131n\u0131rlay\u0131n<\/li>\n\n\n\n<li>Ayr\u0131 fon toplama ve bilimsel y\u00f6netim yap\u0131lar\u0131<\/li>\n\n\n\n<li>Ba\u011f\u0131ms\u0131z denetimleri uygulamaya koyun<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"policy-recommendations\"><strong>Politika \u00d6nerileri<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Hasta \u00f6rg\u00fctleri i\u00e7in zorunlu bilgilendirme standartlar\u0131<\/li>\n\n\n\n<li>Uluslararas\u0131 kar amac\u0131 g\u00fctmeyen kurulu\u015flar\u0131n \u015feffafl\u0131k \u00e7er\u00e7eveleriyle uyum<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"cultural-shift\"><strong>K\u00fclt\u00fcrel De\u011fi\u015fim<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u201cFaaliyet tabanl\u0131\u201d raporlamadan \u201csonu\u00e7 tabanl\u0131\u201d hesap verebilirli\u011fe<\/li>\n\n\n\n<li>G\u00f6r\u00fcn\u00fcrl\u00fckten do\u011frulanabilir etkiye<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"beyond-assistance-the-true-mission-of-dmd-associations\"><strong>Yard\u0131m\u0131n \u00d6tesinde: DMD Derneklerinin Ger\u00e7ek Misyonu<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi (DMD) olan \u00e7ocuklara ak\u00fcl\u00fc tekerlekli sandalye ve benzeri yard\u0131mc\u0131 cihazlar sa\u011flaman\u0131n tart\u0131\u015f\u0131lmaz bir de\u011feri vard\u0131r.<\/strong> Bu m\u00fcdahaleler hareketlili\u011fi, konforu ve g\u00fcnl\u00fck ya\u015fam kalitesini iyile\u015ftirir ve genellikle aileler i\u00e7in an\u0131nda ve g\u00f6zle g\u00f6r\u00fcl\u00fcr bir fark yarat\u0131r. <strong>Ancak, bu t\u00fcr bireysel destek \u00e7abalar\u0131 \u00f6nemli olsa da, DMD derneklerinin birincil misyonunu olu\u015fturmamal\u0131d\u0131r.<\/strong> \u0130lerleyici ve ya\u015fam\u0131 s\u0131n\u0131rlayan bir hastal\u0131kta, \u00f6ncelikle k\u0131sa vadeli rahatlamaya odaklanmak, dikkati ve kaynaklar\u0131 daha geni\u015f bir hedeften, yani hastal\u0131\u011f\u0131n seyrini de\u011fi\u015ftirmekten uzakla\u015ft\u0131rma riskini ta\u015f\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DMD derneklerinin temel sorumlulu\u011fu, sistemik ilerleme i\u00e7in kataliz\u00f6r g\u00f6revi g\u00f6rmek olmal\u0131d\u0131r. Bu, ba\u011f\u0131\u015flar\u0131 stratejik olarak klinik ara\u015ft\u0131rmalar\u0131 ilerletmeye y\u00f6nlendirmek, uluslararas\u0131 klinik \u00e7al\u0131\u015fmalara eri\u015fimi kolayla\u015ft\u0131rmak ve d\u00fczenleyici kurumlarca onaylanm\u0131\u015f tedavileri \u00fclkelerine getirmek i\u00e7in \u00e7al\u0131\u015fmak anlam\u0131na gelir.<\/strong> ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA) ve Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) gibi b\u00fcy\u00fck d\u00fczenleyici kurumlar taraf\u0131ndan onaylanan tedaviler, y\u0131llarca s\u00fcren bilimsel ilerlemeyi temsil etmekte ve hastal\u0131k seyrini de\u011fi\u015ftirme konusunda somut bir umut sunmaktad\u0131r. <strong>D\u00fczenleyici kurumlarla etkile\u015fime, sa\u011fl\u0131k sistemi entegrasyonuna ve hasta eri\u015fim yollar\u0131na \u00f6ncelik veren dernekler, \u00f6ncelikle izole yard\u0131m \u00e7abalar\u0131na odaklanan derneklere k\u0131yasla uzun vadeli sonu\u00e7lara \u00e7ok daha \u00f6nemli katk\u0131lar sa\u011flamaktad\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sonu\u00e7 olarak, bir derne\u011fin etkisinin \u00f6l\u00e7\u00fcs\u00fc da\u011f\u0131t\u0131lan cihaz say\u0131s\u0131 de\u011fil, etkili tedavilere eri\u015fimi ne kadar h\u0131zland\u0131rd\u0131\u011f\u0131 ve bilimsel ilerlemeyi ne kadar destekledi\u011fi olmal\u0131d\u0131r.<\/strong> DMD&#039;den etkilenen aileler, tedaviye eri\u015fimdeki gecikmelerin geri d\u00f6n\u00fc\u015f\u00fc olmayan sonu\u00e7lara yol a\u00e7abilece\u011fi dar bir tedavi penceresiyle kar\u015f\u0131 kar\u015f\u0131yad\u0131r. <strong>Bu nedenle, ba\u011f\u0131\u015flar sadece g\u00fcnl\u00fck ya\u015fam\u0131 desteklemek i\u00e7in de\u011fil, ayn\u0131 zamanda ya\u015fam s\u00fcresini uzatan ve ya\u015fam kalitesini temel d\u00fczeyde iyile\u015ftiren tedavilere y\u00f6nelik anlaml\u0131 ve \u00f6l\u00e7\u00fclebilir ilerlemeyi sa\u011flamak i\u00e7in de kullan\u0131lmal\u0131d\u0131r.<\/strong> Dengeli bir yakla\u015f\u0131m \u015fartt\u0131r; ancak ara\u015ft\u0131rma, klinik \u00e7al\u0131\u015fmalar ve tedaviye eri\u015fim konular\u0131na g\u00fc\u00e7l\u00fc bir vurgu yap\u0131lmad\u0131\u011f\u0131 takdirde, misyon tamamlanmam\u0131\u015f kal\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"if-no-research-and-no-clinical-trial-rethink-about-making-donation\"><strong>E\u011fer ara\u015ft\u0131rma ve klinik deneme yoksa: Ba\u011f\u0131\u015f yapmay\u0131 yeniden d\u00fc\u015f\u00fcn\u00fcn.<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E\u011fer \u00fclkenizdeki DMD dernekleri veya vak\u0131flar\u0131 toplad\u0131klar\u0131 ba\u011f\u0131\u015flar\u0131 klinik ara\u015ft\u0131rmalara, aktif denemelere veya onaylanm\u0131\u015f tedavileri hastalara ula\u015ft\u0131rmaya y\u00f6nelik somut \u00e7abalara y\u00f6nlendirmiyorsa, bu durum misyonlar\u0131yla uyumluluklar\u0131 konusunda ciddi endi\u015feler do\u011furur.<\/strong> Duchenne kas distrofisi gibi agresif ve zaman a\u00e7\u0131s\u0131ndan hassas bir hastal\u0131kta, tedavi s\u00fcrecini h\u0131zland\u0131rmak i\u00e7in her kaynak stratejik olarak tahsis edilmelidir. Ba\u011f\u0131\u015flar yaln\u0131zca kurumsal faaliyetleri s\u00fcrd\u00fcrmemeli, \u00f6l\u00e7\u00fclebilir bilimsel ve klinik sonu\u00e7lar \u00fcretmelidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ailelerin ve ba\u011f\u0131\u015f\u00e7\u0131lar\u0131n, ba\u011f\u0131\u015flar\u0131n nas\u0131l kullan\u0131ld\u0131\u011f\u0131na dair soru sorma hakk\u0131 ve sorumlulu\u011fu vard\u0131r. \u015eeffafl\u0131k, ayr\u0131nt\u0131l\u0131 raporlama ve etkinin net kan\u0131t\u0131 iste\u011fe ba\u011fl\u0131 de\u011fil, temel y\u00fck\u00fcml\u00fcl\u00fcklerdir. <strong>Bir kurulu\u015f, ara\u015ft\u0131rma s\u00fcre\u00e7lerine nas\u0131l katk\u0131da bulundu\u011funu, klinik \u00e7al\u0131\u015fmalara eri\u015fimi nas\u0131l destekledi\u011fini veya tedaviye eri\u015filebilirli\u011fi nas\u0131l art\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6steremiyorsa, etkinli\u011fi ele\u015ftirel bir \u015fekilde yeniden de\u011ferlendirilmelidir.<\/strong> Duygusal \u00e7a\u011fr\u0131lar asla do\u011frulanabilir sonu\u00e7lar\u0131n yerini almamal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu ko\u015fullar alt\u0131nda ba\u011f\u0131\u015f yapmamay\u0131 se\u00e7mek, ilgisizlik anlam\u0131na gelmez; aksine hesap verebilirlik talebidir. <strong>Bu, ba\u011f\u0131\u015f\u00e7\u0131 g\u00fcveninin g\u00f6r\u00fcn\u00fcrl\u00fck yoluyla de\u011fil, etki yoluyla kazan\u0131lmas\u0131 gerekti\u011fi konusunda net bir mesaj veriyor.<\/strong> Sadece ara\u015ft\u0131rma, inovasyon ve hasta eri\u015fimine \u00f6ncelik veren kurulu\u015flar\u0131 desteklemek, ekosistemi ger\u00e7ekten \u00f6nemli sonu\u00e7lara do\u011fru kayd\u0131rmaya yard\u0131mc\u0131 olacakt\u0131r: daha uzun ya\u015fam s\u00fcreleri, daha iyi bak\u0131m kalitesi ve DMD&#039;ye kar\u015f\u0131 ger\u00e7ek ilerleme.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"critical-fa-qs-from-dmd-families-demanding-transparency-and-real-impact\"><strong><strong>DMD Hastal\u0131\u011f\u0131 Olan Ailelerden Kritik S\u0131k\u00e7a Sorulan Sorular: \u015eeffafl\u0131k ve Ger\u00e7ek Etki Talebi<\/strong><\/strong><\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1774515397458\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Toplad\u0131\u011f\u0131n\u0131z ba\u011f\u0131\u015flar\u0131n ne kadar\u0131 do\u011frudan bilimsel ara\u015ft\u0131rmalara ve klinik denemelere gidiyor?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>\u201cProgram giderleri\u201d gibi geni\u015f kategoriler yerine, net bir y\u00fczde istiyoruz. Laboratuvar ara\u015ft\u0131rmalar\u0131na, preklinik \u00e7al\u0131\u015fmalara ve aktif klinik denemelere tam olarak ne kadar fon ayr\u0131l\u0131yor?<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515805118\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Finanse etti\u011finiz ara\u015ft\u0131rmadan elde etti\u011finiz \u00f6l\u00e7\u00fclebilir sonu\u00e7lar\u0131 g\u00f6sterebilir misiniz?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Fonlaman\u0131z sayesinde do\u011frudan ortaya \u00e7\u0131kan hakemli yay\u0131nlar, klinik \u00e7al\u0131\u015fmalar veya onaylanm\u0131\u015f tedaviler nelerdir? Faaliyetlerle ilgilenmiyoruz; do\u011frulanabilir sonu\u00e7lar istiyoruz.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515816908\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ba\u011f\u0131\u015flar\u0131m\u0131z\u0131n ne kadar\u0131 seyahat, konferans ve toplant\u0131lara harcan\u0131yor?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>\u0130\u015f birli\u011finin \u00f6nemli oldu\u011funu anl\u0131yoruz, ancak seyahat ve etkinlikler i\u00e7in y\u0131ll\u0131k b\u00fct\u00e7e ne kadar ve bu harcamalar ne gibi somut sonu\u00e7lar do\u011furdu?<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515823379\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ayr\u0131nt\u0131l\u0131 finansal raporlar neden tam olarak \u015feffaf ve anla\u015f\u0131lmas\u0131 kolay de\u011fil?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Raporlar neden birden fazla harcamay\u0131 belirsiz kategoriler alt\u0131nda grupland\u0131r\u0131yor? Aileler neden ba\u011f\u0131\u015flar\u0131n nas\u0131l harcand\u0131\u011f\u0131na dair sat\u0131r sat\u0131r ayr\u0131nt\u0131l\u0131 bilgilere eri\u015femiyor?<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515836543\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Finanse etti\u011finiz projelerin ba\u015far\u0131 oran\u0131n\u0131 takip ediyor musunuz?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Finanse edilen t\u00fcm ara\u015ft\u0131rma projeleri aras\u0131nda:<\/p>\n<p>\u2022 Ka\u00e7 ki\u015fi klinik denemelere ge\u00e7ti?<br \/>\u2022 Ka\u00e7 ki\u015fi ba\u015far\u0131s\u0131z oldu?<br \/>\u2022 Yat\u0131r\u0131m getirisini (ROI) bilimsel terimlerle nas\u0131l de\u011ferlendirirsiniz?<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515871509\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ara\u015ft\u0131rma projelerine fon sa\u011flan\u0131p sa\u011flanmayaca\u011f\u0131na karar verirken hangi kriterleri kullan\u0131yorsunuz?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Kararlar \u015funlara m\u0131 dayan\u0131yor:<\/p>\n<p>\u2022 Bilimsel de\u011feri ve ba\u015far\u0131 olas\u0131l\u0131\u011f\u0131?<br \/>\u2022 \u0130li\u015fkiler ve a\u011flar?<br \/>\u2022 Kurumsal prestij?<\/p>\n<p><strong>Ba\u011f\u0131ms\u0131z bir bilimsel inceleme s\u00fcreci var m\u0131?<\/strong><\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515921814\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ba\u011f\u0131\u015flanan fonlar\u0131n d\u00fc\u015f\u00fck etkili veya tekrarlayan faaliyetlere harcanmamas\u0131n\u0131 nas\u0131l sa\u011fl\u0131yorsunuz?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>A\u015fa\u011f\u0131dakileri \u00f6nlemek i\u00e7in hangi g\u00fcvenlik \u00f6nlemleri al\u0131nm\u0131\u015ft\u0131r:<\/p>\n<p>\u2022 Gereksiz ara\u015ft\u0131rmalar\u0131n finansman\u0131<br \/>\u2022 \u00c7eviri potansiyeli olmayan projeleri desteklemek<br \/>\u2022 Hastaya fayda sa\u011flamayan faaliyetlere yap\u0131lan harcamalar<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515949457\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">Ba\u011f\u0131\u015f\u00e7\u0131lara neden ilerleme durumu panolar\u0131 veya ger\u00e7ek zamanl\u0131 g\u00fcncellemeler sunulmuyor?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Neden g\u00f6remiyoruz:<\/p>\n<p>\u2022 \u015eu anda hangi projeler finanse ediliyor?<br \/>\u2022 \u0130lerleme durumlar\u0131<br \/>\u2022 Elde edilen veya ka\u00e7\u0131r\u0131lan d\u00f6n\u00fcm noktalar\u0131<\/p>\n<p>Bu \u015feffafl\u0131k d\u00fczeyine neden hala ula\u015f\u0131lam\u0131yor?<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515973917\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">B\u00fct\u00e7enizin y\u00fczde ka\u00e7\u0131 y\u00f6netim giderlerine ve maa\u015flara harcan\u0131yor?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Profesyonel y\u00f6netime duyulan ihtiyaca sayg\u0131 duyuyoruz, ancak:<\/p>\n<p>\u2022 Toplam y\u00f6netim gideri oran\u0131 nedir?<br \/>\u2022 Y\u00f6netici maa\u015flar\u0131, ger\u00e7ek ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131yla nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131yor?<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1774515992914\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">E\u011fer ba\u011f\u0131\u015flar \u00f6l\u00e7\u00fclebilir bir ilerleme sa\u011flam\u0131yorsa, hangi hesap verebilirlik mekanizmalar\u0131 mevcuttur?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Hedeflere ula\u015f\u0131lamamas\u0131 durumunda:<\/p>\n<p>\u2022 Kim sorumlu?<br \/>\u2022 Finansman stratejileri g\u00f6zden ge\u00e7irildi mi?<br \/>\u2022 Y\u00f6netim veya politikalar de\u011fi\u015ftirildi mi?<\/p>\n<p>Yoksa sistem sonu\u00e7lardan ba\u011f\u0131ms\u0131z olarak de\u011fi\u015fmeden mi devam eder?<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"closing-perspective\"><strong>Kapan\u0131\u015f Bak\u0131\u015f A\u00e7\u0131s\u0131<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bunlar d\u00fc\u015fmanca sorular de\u011fil, gerekli sorular.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Onlar \u015funlar\u0131 hak ediyorlar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u015eeffafl\u0131k<\/strong><\/li>\n\n\n\n<li><strong>Hesap verebilirlik<\/strong><\/li>\n\n\n\n<li><strong>\u00d6l\u00e7\u00fclebilir ilerleme<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"final-thoughts\"><strong>Son D\u00fc\u015f\u00fcnceler<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DMD dernekleri, y\u0131k\u0131c\u0131 bir hastal\u0131\u011fa kar\u015f\u0131 m\u00fccadelede kritik bir konumda yer almaktad\u0131r. Katk\u0131lar\u0131 \u00f6nemli olsa da, mevcut fon tahsis modeli yeterli \u015feffafl\u0131k, hesap verebilirlik ve \u00f6l\u00e7\u00fclebilir etki a\u00e7\u0131s\u0131ndan yetersizdir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u011f\u0131\u015flar sadece kurumsal faaliyetleri s\u00fcrd\u00fcrmekle kalmamal\u0131, bilimsel ilerlemeyi h\u0131zland\u0131rmal\u0131 ve hasta sonu\u00e7lar\u0131n\u0131 iyile\u015ftirmelidir. Yap\u0131sal reformlar olmadan, de\u011ferli kaynaklar\u0131n d\u00fc\u015f\u00fck etkili faaliyetlere da\u011f\u0131lmaya devam etmesi ger\u00e7ek bir risktir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD tedavisinin gelece\u011fi yaln\u0131zca bilimsel yeniliklere de\u011fil, ayn\u0131 zamanda bize emanet edilen kaynaklar\u0131 ne kadar etkili bir \u015fekilde tahsis etti\u011fimize de ba\u011fl\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-associations-failure-treatment-access\/\">DMD Derneklerinin Sistematik Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/a><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">\u00dclkenizdeki DMD derneklerinin web sitelerini ziyaret edin, faaliyetlerini inceleyin ve ba\u011f\u0131\u015flar\u0131n klinik denemeler, ara\u015ft\u0131rmalar ve onaylanm\u0131\u015f tedavilerin \u00fclkenize getirilmesi i\u00e7in kullan\u0131lmas\u0131nda \u0131srar edin.<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sources-and-academic-references\">Kaynaklar ve Akademik Referanslar<\/h2>\n\n\n<ol class=\"wp-block-footnotes\"><li id=\"96084803-54f1-4918-9709-737f9813c4a8\"><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0166497224001627\" target=\"_blank\" rel=\"noopener\">Ba\u015fka kaynaklardan elde edilen bilgiler: Akademik kat\u0131l\u0131m\u0131n bilimsel etki \u00fczerindeki olumlu etkisi<\/a> <a href=\"#96084803-54f1-4918-9709-737f9813c4a8-link\" aria-label=\"Dipnot tak\u0131m\u0131na atla 1\">\u21a9\ufe0e<\/a><\/li><\/ol>","protected":false},"excerpt":{"rendered":"<p>Where do DMD associations spend the donations they receive, and how much of it truly supports scientific research and clinical trials? Are donations being directed toward therapies that can change lives, or diluted across administrative costs, conferences, and travel? Why are detailed financial breakdowns often unclear or difficult to access? Can benefactors and families see [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7113,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"[{\"content\":\"<a href=\\\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0166497224001627\\\">Sourcing insights elsewhere: The positive influence of academic engagement on scientific impact<\/a>\",\"id\":\"96084803-54f1-4918-9709-737f9813c4a8\"}]"},"categories":[282],"tags":[229,588,230],"class_list":["post-7110","post","type-post","status-publish","format-standard","has-post-thumbnail","category-editorials","tag-dmd-associations","tag-donations","tag-duchenne-associations"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/7110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=7110"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/7110\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/7113"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=7110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=7110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=7110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}